Affiliations: Department of Biochemistry, Genetic and Immunology,
Facultad de Biología, Universidad de Vigo, Vigo, Spain | Unit of Interventional Bronchopleural Pathology,
Pneumology Department of Complejo Hospitalario, Universitario de Vigo, Vigo,
Spain
Note: [] Corresponding author: María Páez de la Cadena,
Department of Biochemistry, Genetic and Immunology, Facultad de
Biología, Universidad de Vigo, 36310 Vigo, Spain. E-mail:
[email protected]
Abstract: Anti-tumor properties assigned to PEDF, beside its role as an
inhibitor of angiogenesis, make it a promising candidate in the search of new
biomarkers for malignancy. In this study levels of PEDF were investigated in
pleural effusions from lung adenocarcinoma and benign inflammatory disease
patients. The mean PEDF concentration in the malignant group was slightly
superior to that in patients suffering benign diseases (4.59 μ g/mL vs 3.97
μg/mL), although the difference did not reach statistical significance (P
0.166). Pleural effusion PEDF levels were not related to gender, age, smoking
habit or pleural effusion size. We also investigated the possible relationship
of PEDF levels in pleural effusion regarding clinicopathological features.
Correlations were found for monocytes (P 0.010) and polymorphonuclear
leukocytes (P 0.023) with PEDF levels in pleural effusion of malignant origin.
